Johnson & Johnson (JNJ): FY25 Q2 earnings call, Jul 16, 2025

Wed, Jul 16Earnings callSpeaker-labelled transcriptJohnson & Johnson

No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jul 16, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

3 matches for “Procedure”; 3 quoted, at least 25 words apart.

Joaquin Duatocompanyprepared

…that will expand our portfolio of tools for safe and streamlined ablation procedures. Third is Shockwave's unique intravascular lithotripsy technology or IVL, which has transformed…

Unknown Analystanalystprepared

…prior year, driven by strength in competitive mapping, new product performance and procedure growth. Abiomed delivered growth of 16.9% with continued strong adoption of Impella…

John Reedcompanyprepared

…launched products in cardiovascular, surgery and vision. We continue to expect normalized procedure volumes and typical seasonality patterns throughout the remainder of the year. Beyond…

Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-07-16:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-07-16:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP